Atish Majumdar
Sales & Marketing at MANKIND PHARMA LIMITED
Profile
Atish Majumdar is currently the Director at Actimed Therapeutics Ltd.
and the President-Sales & Marketing at Mankind Pharma Ltd.
He completed his undergraduate degree from the University of Calcutta.
Atish Majumdar active positions
Companies | Position | Start |
---|---|---|
MANKIND PHARMA LIMITED | Sales & Marketing | 08/11/2019 |
Actimed Therapeutics Ltd.
Actimed Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Actimed Therapeutics Ltd. is a British clinical stage specialty pharmaceutical company that focuses on bringing innovation to the treatment of muscle wasting disorders. Actimed is based in Ascot, UK. Actimed's lead product, ACM-001 (S-pindolol), targets multiple biological pathways that drive cachexia and has generated promising proof of concept data in a phase II clinical trial in patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). The company is currently preparing for further clinical studies of cachexia in these two cancer types. The company was founded in 2017 by Stefan D. Anker and Andrew Justin Stewart Coats, two world-leading physicians in muscle wasting research, together with Yann Colardelle, a professional in communications and medical education. | Director/Board Member | 03/01/2023 |
Training of Atish Majumdar
University of Calcutta | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
MANKIND PHARMA LIMITED | Health Technology |
Private companies | 1 |
---|---|
Actimed Therapeutics Ltd.
Actimed Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Actimed Therapeutics Ltd. is a British clinical stage specialty pharmaceutical company that focuses on bringing innovation to the treatment of muscle wasting disorders. Actimed is based in Ascot, UK. Actimed's lead product, ACM-001 (S-pindolol), targets multiple biological pathways that drive cachexia and has generated promising proof of concept data in a phase II clinical trial in patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). The company is currently preparing for further clinical studies of cachexia in these two cancer types. The company was founded in 2017 by Stefan D. Anker and Andrew Justin Stewart Coats, two world-leading physicians in muscle wasting research, together with Yann Colardelle, a professional in communications and medical education. | Commercial Services |
- Stock Market
- Insiders
- Atish Majumdar